BioSpace News Archive

MediPharm Labs Corp., a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce its participation at upcoming virtual investor conferences.

Obalon Therapeutics, Inc., a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced its financial results for the first quarter ended March 31, 2020 and provided a business update.

Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, announced the successful completion of a $50 million Series C financing.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced the pricing of $100 million aggregate principal amount of 4.250% convertible senior notes due 2025 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.

Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, announced the hiring of Jackie Schumacher to lead Global Regulatory Affairs.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the National Medical Products Administration (NMPA) in China has approved Dupixent® (dupilumab) for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, today announced that the FDA has provided Acasti with a written response to its Type C Meeting request and briefing package. The FDA confirmed that it will require piv

Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also observed NEWARK, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced new data from a previously compl

AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has entered into a record, three-year strategic cancer screening collaboration contract with Beijing Yuan Jian Health Management Co., Ltd. in China, which has been a client of the Company for the past two years. T

-- MyoKardia to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 --